Influence of sustained viral response on the regression of fibrosis and portal hypertension in cirrhotic HCV patients treated with antiviral triple therapy

Background and aims: The regression of liver fibrosis and portal hypertension (PH) and their influence on the natural history of compensated hepatitis C virus (HCV)-related cirrhosis has not been studied previously. Our objective was to evaluate the influence of sustained virologic response (SVR) on the portal pressure gradient (HVPG) and non-invasive parameters of PH and prognostic factors of response. Methods: Sixteen patients with compensated HCV genotype 1-related cirrhosis with PH (HVPG &gt; 6 mmHg) without beta-blocker therapy were considered as candidates for PEG&#945;2a + RBV + BOC (48 weeks; lead-in and accepted stopping rules). A hemodynamic study and Fibroscan® were performed at baseline, at eight weeks and, in the case of SVR, 24 weeks after treatment. In each hemodynamic study, serum samples were analyzed for inflammatory biomarkers associated with PH. Results: In eight cases, SVR was obtained; five patients relapsed, and treatment was stopped early for non-response to lead in (one case) and a decrease of < 3 log at week 8 (two patients). Compared to baseline, there was a significant decrease in HVPG and Fibroscan® at weeks 8 and 72 (10.31 ± 4.3 vs 9.4 ± 5.04 vs 6.1 ± 3.61 mmHg, p < 0.0001 and 21.3 ± 14.5 vs 16.2 ± 9.5 vs 6.4 ± 4.5 kPa, p < 0.0001, respectively). The average HVPG decrease in SVR was 40.8 ± 17.53%, achieving an HVPG < 6 mmHg in five patients (62.5%) and a Fibroscan® < 7.1 kPa in three patients (37.5%). Conclusions: Complete hemodynamic response (HVPG < 6 mmHg) and fibrosis regression (Fibroscan® < 7.1 kPa) occur in more than half and one-third of patients achieving SVR, respectively, and must be another target in cirrhotic patients with SVR.

Saved in:
Bibliographic Details
Main Authors: Puente,Ángela, Cabezas,Joaquín, López Arias,María Jesús, Fortea,José Ignacio, Arias,María Teresa, Estébanez,Ángel, Casafont,Fernando, Fábrega,Emilio, Crespo,Javier
Format: Digital revista
Language:English
Published: Sociedad Española de Patología Digestiva 2017
Online Access:http://scielo.isciii.es/scielo.php?script=sci_arttext&pid=S1130-01082017000100004
Tags: Add Tag
No Tags, Be the first to tag this record!
id oai:scielo:S1130-01082017000100004
record_format ojs
spelling oai:scielo:S1130-010820170001000042017-05-29Influence of sustained viral response on the regression of fibrosis and portal hypertension in cirrhotic HCV patients treated with antiviral triple therapyPuente,ÁngelaCabezas,JoaquínLópez Arias,María JesúsFortea,José IgnacioArias,María TeresaEstébanez,ÁngelCasafont,FernandoFábrega,EmilioCrespo,Javier Portal pressure gradient Portal hypertension Triple therapy SVR Fibroscan® Background and aims: The regression of liver fibrosis and portal hypertension (PH) and their influence on the natural history of compensated hepatitis C virus (HCV)-related cirrhosis has not been studied previously. Our objective was to evaluate the influence of sustained virologic response (SVR) on the portal pressure gradient (HVPG) and non-invasive parameters of PH and prognostic factors of response. Methods: Sixteen patients with compensated HCV genotype 1-related cirrhosis with PH (HVPG &gt; 6 mmHg) without beta-blocker therapy were considered as candidates for PEG&#945;2a + RBV + BOC (48 weeks; lead-in and accepted stopping rules). A hemodynamic study and Fibroscan® were performed at baseline, at eight weeks and, in the case of SVR, 24 weeks after treatment. In each hemodynamic study, serum samples were analyzed for inflammatory biomarkers associated with PH. Results: In eight cases, SVR was obtained; five patients relapsed, and treatment was stopped early for non-response to lead in (one case) and a decrease of < 3 log at week 8 (two patients). Compared to baseline, there was a significant decrease in HVPG and Fibroscan® at weeks 8 and 72 (10.31 ± 4.3 vs 9.4 ± 5.04 vs 6.1 ± 3.61 mmHg, p < 0.0001 and 21.3 ± 14.5 vs 16.2 ± 9.5 vs 6.4 ± 4.5 kPa, p < 0.0001, respectively). The average HVPG decrease in SVR was 40.8 ± 17.53%, achieving an HVPG < 6 mmHg in five patients (62.5%) and a Fibroscan® < 7.1 kPa in three patients (37.5%). Conclusions: Complete hemodynamic response (HVPG < 6 mmHg) and fibrosis regression (Fibroscan® < 7.1 kPa) occur in more than half and one-third of patients achieving SVR, respectively, and must be another target in cirrhotic patients with SVR.Sociedad Española de Patología DigestivaRevista Española de Enfermedades Digestivas v.109 n.1 20172017-01-01journal articletext/htmlhttp://scielo.isciii.es/scielo.php?script=sci_arttext&pid=S1130-01082017000100004en
institution SCIELO
collection OJS
country España
countrycode ES
component Revista
access En linea
databasecode rev-scielo-es
tag revista
region Europa del Sur
libraryname SciELO
language English
format Digital
author Puente,Ángela
Cabezas,Joaquín
López Arias,María Jesús
Fortea,José Ignacio
Arias,María Teresa
Estébanez,Ángel
Casafont,Fernando
Fábrega,Emilio
Crespo,Javier
spellingShingle Puente,Ángela
Cabezas,Joaquín
López Arias,María Jesús
Fortea,José Ignacio
Arias,María Teresa
Estébanez,Ángel
Casafont,Fernando
Fábrega,Emilio
Crespo,Javier
Influence of sustained viral response on the regression of fibrosis and portal hypertension in cirrhotic HCV patients treated with antiviral triple therapy
author_facet Puente,Ángela
Cabezas,Joaquín
López Arias,María Jesús
Fortea,José Ignacio
Arias,María Teresa
Estébanez,Ángel
Casafont,Fernando
Fábrega,Emilio
Crespo,Javier
author_sort Puente,Ángela
title Influence of sustained viral response on the regression of fibrosis and portal hypertension in cirrhotic HCV patients treated with antiviral triple therapy
title_short Influence of sustained viral response on the regression of fibrosis and portal hypertension in cirrhotic HCV patients treated with antiviral triple therapy
title_full Influence of sustained viral response on the regression of fibrosis and portal hypertension in cirrhotic HCV patients treated with antiviral triple therapy
title_fullStr Influence of sustained viral response on the regression of fibrosis and portal hypertension in cirrhotic HCV patients treated with antiviral triple therapy
title_full_unstemmed Influence of sustained viral response on the regression of fibrosis and portal hypertension in cirrhotic HCV patients treated with antiviral triple therapy
title_sort influence of sustained viral response on the regression of fibrosis and portal hypertension in cirrhotic hcv patients treated with antiviral triple therapy
description Background and aims: The regression of liver fibrosis and portal hypertension (PH) and their influence on the natural history of compensated hepatitis C virus (HCV)-related cirrhosis has not been studied previously. Our objective was to evaluate the influence of sustained virologic response (SVR) on the portal pressure gradient (HVPG) and non-invasive parameters of PH and prognostic factors of response. Methods: Sixteen patients with compensated HCV genotype 1-related cirrhosis with PH (HVPG &gt; 6 mmHg) without beta-blocker therapy were considered as candidates for PEG&#945;2a + RBV + BOC (48 weeks; lead-in and accepted stopping rules). A hemodynamic study and Fibroscan® were performed at baseline, at eight weeks and, in the case of SVR, 24 weeks after treatment. In each hemodynamic study, serum samples were analyzed for inflammatory biomarkers associated with PH. Results: In eight cases, SVR was obtained; five patients relapsed, and treatment was stopped early for non-response to lead in (one case) and a decrease of < 3 log at week 8 (two patients). Compared to baseline, there was a significant decrease in HVPG and Fibroscan® at weeks 8 and 72 (10.31 ± 4.3 vs 9.4 ± 5.04 vs 6.1 ± 3.61 mmHg, p < 0.0001 and 21.3 ± 14.5 vs 16.2 ± 9.5 vs 6.4 ± 4.5 kPa, p < 0.0001, respectively). The average HVPG decrease in SVR was 40.8 ± 17.53%, achieving an HVPG < 6 mmHg in five patients (62.5%) and a Fibroscan® < 7.1 kPa in three patients (37.5%). Conclusions: Complete hemodynamic response (HVPG < 6 mmHg) and fibrosis regression (Fibroscan® < 7.1 kPa) occur in more than half and one-third of patients achieving SVR, respectively, and must be another target in cirrhotic patients with SVR.
publisher Sociedad Española de Patología Digestiva
publishDate 2017
url http://scielo.isciii.es/scielo.php?script=sci_arttext&pid=S1130-01082017000100004
work_keys_str_mv AT puenteangela influenceofsustainedviralresponseontheregressionoffibrosisandportalhypertensionincirrhotichcvpatientstreatedwithantiviraltripletherapy
AT cabezasjoaquin influenceofsustainedviralresponseontheregressionoffibrosisandportalhypertensionincirrhotichcvpatientstreatedwithantiviraltripletherapy
AT lopezariasmariajesus influenceofsustainedviralresponseontheregressionoffibrosisandportalhypertensionincirrhotichcvpatientstreatedwithantiviraltripletherapy
AT forteajoseignacio influenceofsustainedviralresponseontheregressionoffibrosisandportalhypertensionincirrhotichcvpatientstreatedwithantiviraltripletherapy
AT ariasmariateresa influenceofsustainedviralresponseontheregressionoffibrosisandportalhypertensionincirrhotichcvpatientstreatedwithantiviraltripletherapy
AT estebanezangel influenceofsustainedviralresponseontheregressionoffibrosisandportalhypertensionincirrhotichcvpatientstreatedwithantiviraltripletherapy
AT casafontfernando influenceofsustainedviralresponseontheregressionoffibrosisandportalhypertensionincirrhotichcvpatientstreatedwithantiviraltripletherapy
AT fabregaemilio influenceofsustainedviralresponseontheregressionoffibrosisandportalhypertensionincirrhotichcvpatientstreatedwithantiviraltripletherapy
AT crespojavier influenceofsustainedviralresponseontheregressionoffibrosisandportalhypertensionincirrhotichcvpatientstreatedwithantiviraltripletherapy
_version_ 1755938733710901248